IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

VIGANO', MAURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.805
NA - Nord America 6.263
AS - Asia 5.917
Continente sconosciuto - Info sul continente non disponibili 1.082
SA - Sud America 488
AF - Africa 145
OC - Oceania 18
Totale 22.718
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.994
GB - Regno Unito 3.631
CN - Cina 1.881
SG - Singapore 1.629
DE - Germania 1.120
IT - Italia 1.080
SE - Svezia 650
RU - Federazione Russa 564
BD - Bangladesh 468
HK - Hong Kong 455
VN - Vietnam 438
FR - Francia 412
UA - Ucraina 346
IN - India 332
BR - Brasile 294
TR - Turchia 227
NL - Olanda 211
IE - Irlanda 198
KR - Corea 192
CA - Canada 172
FI - Finlandia 165
EU - Europa 130
PL - Polonia 120
CO - Colombia 99
DK - Danimarca 85
JP - Giappone 65
GR - Grecia 56
BE - Belgio 51
ID - Indonesia 45
AR - Argentina 42
MX - Messico 39
CI - Costa d'Avorio 34
ES - Italia 29
IQ - Iraq 24
UZ - Uzbekistan 21
PH - Filippine 20
TH - Thailandia 19
RO - Romania 18
MY - Malesia 15
VE - Venezuela 15
AU - Australia 14
EC - Ecuador 14
CH - Svizzera 13
EG - Egitto 13
SA - Arabia Saudita 12
TN - Tunisia 12
ZA - Sudafrica 12
DZ - Algeria 11
KE - Kenya 11
ET - Etiopia 10
PT - Portogallo 10
SL - Sierra Leone 10
AT - Austria 9
PK - Pakistan 9
AE - Emirati Arabi Uniti 8
CL - Cile 8
JM - Giamaica 8
TT - Trinidad e Tobago 8
CZ - Repubblica Ceca 6
IL - Israele 6
LK - Sri Lanka 6
MA - Marocco 6
PA - Panama 6
CR - Costa Rica 5
GH - Ghana 5
HN - Honduras 5
IR - Iran 5
JO - Giordania 5
NP - Nepal 5
PE - Perù 5
UY - Uruguay 5
BG - Bulgaria 4
DO - Repubblica Dominicana 4
GE - Georgia 4
KZ - Kazakistan 4
NI - Nicaragua 4
PR - Porto Rico 4
RS - Serbia 4
SV - El Salvador 4
BO - Bolivia 3
BY - Bielorussia 3
LU - Lussemburgo 3
LY - Libia 3
MD - Moldavia 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
PY - Paraguay 3
SI - Slovenia 3
TW - Taiwan 3
BF - Burkina Faso 2
CU - Cuba 2
EE - Estonia 2
GT - Guatemala 2
HR - Croazia 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
MM - Myanmar 2
QA - Qatar 2
RE - Reunion 2
Totale 21.732
Salva come PNG Salva come JPEG
Città #
Southend 3.430
Singapore 956
Ashburn 641
Chandler 619
Hong Kong 414
Beijing 412
Frankfurt am Main 326
Seattle 317
Jacksonville 304
Milan 304
San Jose 273
Santa Clara 268
Princeton 232
Dublin 184
Wilmington 179
Los Angeles 165
Ann Arbor 153
New York 145
Nanjing 144
Council Bluffs 142
Bengaluru 139
Ho Chi Minh City 137
Hanoi 135
Mountain View 131
Dallas 115
Dearborn 115
Redmond 115
Boardman 111
Warsaw 103
Sunnyvale 95
Lauterbourg 94
Buffalo 91
Serra 91
Toronto 81
Andover 80
Bogotá 80
Fairfield 80
Sakarya 79
Des Moines 78
Moscow 74
Shanghai 73
Woodbridge 64
Rome 61
Somerville 57
Helsinki 56
Guangzhou 53
Jinan 50
Munich 50
Tianjin 45
Hebei 44
Shenyang 44
Tokyo 41
Athens 40
Brussels 40
Hefei 40
Phoenix 40
Grafing 37
Houston 36
Nanchang 36
Abidjan 34
Cangzhou 34
São Paulo 34
Chicago 33
Saint Petersburg 33
Turin 33
Zhengzhou 30
Hangzhou 27
Redwood City 27
Kiez 26
Da Nang 25
Berlin 24
Bitonto 24
Mumbai 24
Changsha 23
Seoul 20
Columbus 19
Fuzhou 19
Haiphong 19
Naples 19
San Diego 19
The Dalles 19
Nürnberg 18
Fremont 17
Shenzhen 17
Istanbul 16
Kunming 15
London 15
Palermo 15
Chennai 14
Menlo Park 14
Nuremberg 14
Orem 14
Washington 14
Bologna 13
Central District 13
Jiaxing 13
Turku 13
Cagliari 12
Cambridge 12
Eitensheim 12
Totale 13.375
Salva come PNG Salva come JPEG
Nome #
Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis 553
Real life experiences in HCV management in 2018 412
Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice : the Italian multicenter experience 400
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice : high efficacy and favorable safety profile over 3 years of treatment 368
Combined lamivudine and adefovir dipivoxil treatment allows safe and long-term compath-1H therapy in refractory B-cell chronic lymphocytic leukemia with HBV reactivation 312
Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H 312
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 307
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices : a 12-year prospective cohort study 305
Excellent 5-year overall survival in patients with HBV-related cirrhosis undergoing liver transplantation for hepatocellular carcinoma 294
Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease 293
Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years 292
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma 278
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease 277
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegykated interferon-α2A in chronic hepatitis C : an in vitro and in vivo study 276
Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics 271
Accuracy of two new predictive models in assessing fibrosis in chronic hepatitis C (CHC) 266
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 260
A response guided approach to peginterferon alfa-2a therapy based on HBsAg levels at weeks 12 and 24 improves response rates in HBeAG-negative, genotype D chronic hepatitis B patients 260
Inhibition of HBV-replication by combined treatment of lamivudine and adefovir dipivoxil allows long-term campath-1H therapy in refractory B-cell chronic lymphoblastic leukemia 250
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 250
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistant patients with HBeAg-negative chronic hepatitis B 248
US features of liver surface nodularity as a predictor of severe fibrosis in chronic hepatitis C 247
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine 245
Lamivudine prophylaxis of hepatitis B reactivation in anti-HBC seroposivive patients undergoing chemotherapy for onco-hematological diseases 244
Clinical implications of HBsAg quantification in patients with chronic hepatitis B 241
Evaluating liver fibrosis in chronic hepatitis c (CHC), accuracy of two new predictive models 238
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistano patients with HBeAg-negative chronic hepatitis B 237
Natural history and clinical impact of cryoglobulins in chronic hepatitis C : 10-year prospective study of 343 patients 237
Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies : two case reports 234
Changes in liver stiffness during entecavir therapy in patients with chronic hepatitis B 229
Combination therapy with adefovir dipivoxil (ADV)and lamivudine (LAM) in LAM-resistant patients enlisted for liver transplantation 228
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 228
Severe hepatic fibrosis in chronic hepatitis C 227
Entecavir is an effective treatment for NUC-naive chronic hepatitis B patients in clinical practice : 48-week data from a large multicenter cohort study 227
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-alpha 2a in chronic hepatitis C : an in vitro and in vivo study 227
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 225
IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients 225
Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis 224
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B 218
Effectiveness of entecavir for the treatment of NUC-naïve chronic hepatitis B patients : A large multicenter cohort study in clinical practice 217
Five years of sequential lam to lam_adv therapy suppresses HBV replication in most hbeag-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma 212
Natural history of HCC developing in HBV-related cirrhotic patients undergoing antiviral treatment with nucleos(t)ide analogues 211
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 211
High risk of renal impairment and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 209
Transient elastography predicts response to prolonged therapy with a nucleoside analog in patients with chronic hepatitis B 204
Low risk of hepatitis B virus reactivation in HBsAg-negative/anti-HBc-positive carriers receiving rituximab for rheumatoid arthritis : a retrospective multicenter Italian study 204
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-α2a in chronic hepatitis C: an in vitro and in vivo study 201
Effectiveness of entecavir for the treatment of nuc-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 200
No evidence for ADV resistance in HBeAg-negative Lamivudine resistant patients treated with LAMIVUDINE-ADEFOVIR combination for 3 years 199
Changes in liver stiffness during entecavir therapy in patients with chronic hepatitis B 199
Transient elastography (TE) accurately predicts liver fibrosis stage in patients with chronic hepatitis B 198
Entecavir for nuc-naïve chronic hepatitis B patients in clinical practice : long-term effectiveness from a large multicenter cohort study in 376 patients 197
Effectiveness of Entecavir for the treatment of NUC-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 196
Low resistance to adefovir combined with lamivudine : a 3-year study of 145 lamivudine-resistant hepatitis B patients 196
Very early add-on adefovir therapy in patients with sub-optimal virological response to lamivudine 193
PegBeLiver study : HBsAg decline at week 24 of extended Peginterferon Alfa-2A (PEG-IFNα-2a) therapy is significantly associated with post-treatment response in HBeAg-negative genotype D patients 193
Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal 193
Six years of “on demand” LAM ± ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis 191
Ruolo delle crioglobuline sieriche nel corso dell'epatopatia cronica HCV-correlata. Studio prospettico di coorte di 343 pazienti 190
Add on Adefovir prevents the emergence of ADV resistance in Lamivudine-resistant patients : a 4-year study 189
No evidence for ADV resistance in HBeAg negative lamivudine resisstant patients treated with lamivudine-adefovir combination for 3 years 187
Hepatitis B virus reverse seroconversion in allogeneic hematopoietic stem cell transplantation 187
Protocol liver biopsies to evaluate severity of recurrent HCV hepatitis : a recent monocentric experience 187
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 185
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants 184
Low risk of hepatitis B reactivation in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 179
Low risk of hepatitis B reactivatioin in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 179
Six years of on demand LAM +/- ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with hbeag-negative cirrhosis 177
Four years of Adefovir add-on in 145 lamivudine resistant patients with chronic hepatitis B : low risk of genotypic resistance to ADV and prevention of virologic breakthrough 177
A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C : a comparison using histology with internal-external validation 177
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 177
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudineresistant chronic hepatitis B 176
Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma 176
Late graft dysfunction (GD) in HBV recurrence-free recipients is associated with serum antinuclear antibodies (ANA) reactivity 174
Acute hepatitis following assumption of a herbal remedy 173
The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin 171
Graft dysfunction (GD) in HBV recurrence free recipience is associated with serum autoantibodies reactivity 171
Systematic review with meta-analysis : do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? 171
Optimal therapy of chronic hepatitis B : how do I treat my HBeAg-negative patients? 171
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 169
Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs) 169
Entecavir for nuc-naïve chronic hepatitis b patients in clinical practice : long-term effectiveness from a large multicenter cohort study in 376 patients 167
AISF position paper on HCV in immunocompromised patients 165
The prognosis and management of inactive HBV carriers 162
Failure of adefovir 20 mg to improve suboptimal response in lamivudine resistant hepatitis B patients treated with adefovir 10 mg and lamivudine 161
Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders 161
Efficacy and safety of pegylated interferon plus ribavirin in patients with hepatitis C recurrence after liver transplantation : a single centre experience 159
High rates of hepatitis B virus riverse seroconversion in anti-HBc carriers undergoing allogeneic bone marrow transplantation 156
Prospective evaluation of staging systems for hepatocellular carcinoma detected during surveillance of cirrhotic patients 156
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy 155
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-α2a in chronic hepatitis C: an in vitro and in vivo study 153
Review article : The potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection 152
Hepatocellular carcinoma in patients with compensated HCV-related cirrhosis responding to interferon : A 5-year follow-up study 150
Progressive decline of HBsAg titers in longterm virological responders to nucleos(t)ide analogue therapy for chronic hepatitis B 149
Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection 147
Safety and tolerability of extended (96 weeks) treatment with peginterferon alfa-2a [40kd] in genotype D patients with HBeAg-negative chronic hepatitis B 146
PegIFN-α2a for the treatment of chronic hepatitis B and C : a 10-year history 138
Treatment of Hepatitis C virus infection in Italy : a consensus report from an expert panel 136
Treatment of hepatitis B : is there still a role for interferon? 134
Low risk of hepatocellular carcinoma recurrence after liver transplantation : a 3-year follow-up study in 78 patients with chronic hepatitis B 133
Totale 21.465
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.149
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.149
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.299 0 79 73 94 62 66 121 121 131 210 81 261
2022/20231.796 230 224 142 251 195 349 33 88 176 29 52 27
2023/20241.205 29 82 39 55 329 118 76 90 38 68 126 155
2024/20252.438 99 276 64 307 217 58 30 218 152 190 241 586
2025/20265.495 583 293 458 318 528 369 670 232 467 457 559 561
2026/2027595 410 185 0 0 0 0 0 0 0 0 0 0
Totale 22.718